Treehill will support FivepHusion with business development, and operational, strategic and transactional expertise while Syneos will help develop the Australian biotech firm’s clinical development and commercialisation capabilities
Deflexifol is a proprietary, novel, and optimised physiological pH formulation from FivepHusion. (Credit: Glsun Mall on Unsplash)
Australian biotechnology company FivepHusion has partnered with strategic and financial advisory firm Treehill Partners and Syneos Health to develop and launch Deflexifol, a new enhanced chemotherapeutic product, in the market.
Under the partnership, New York-based Treehill Partners will support FivepHusion with integrated business development, and operational, strategic, and transactional expertise.
Syneos Health, a biopharmaceutical solutions provider, will also help to develop FivepHusion’s integrated clinical development and commercialisation capabilities.
This partnership aims to strategically and effectively advance the development and global market launch of Deflexifol.
FivepHusion CEO and managing director Christian Toouli said: “This is a very exciting time for FivepHusion. We are at a crucial stage in our growth strategy.
“By collaborating with Treehill Partners and Syneos Health, we believe we are positioned to successfully bring our development work on Deflexifol to global markets, including in the US, Europe and Asia.
“This collaboration represents a unique working model to the industry. Through the combined strength and competency of three industry leaders, we intend to maximise our progress on the development of Deflexifol and quickly bring innovative oncology medicines to patients in need.”
FivepHusion’s Deflexifol is a proprietary, optimised physiological pH formulation. It is designed to co-administer the chemotherapeutic agent 5-fluorouracil (5-FU) and its biomodulator leucovorin (LV).
The drug candidate is being developed for cancers with high unmet medical needs like paediatric ependymoma, a rare and deadly brain cancer found in very young children.
Syneos Health chief business officer Christian Tucat said: “We’re excited to collaborate with FivepHusion and Treehill Partners to help bring Deflexifol to patients.
“Leveraging our deep therapeutic and global expertise, Syneos Health is pleased to contribute to accelerating the clinical development and commercialization of this important new therapy.”